PMDA Follow-up E2B Is Scheduled Differently By 'Allow Multiple Reports For Marketed/Investigational Drugs' Checkbox
(Doc ID 2112672.1)
Last updated on AUGUST 11, 2020
Applies to:Oracle Argus Safety Japan - Version 7.0.3 and later
Information in this document applies to any platform.
After PMDA E2B has been submitted for a license of Product X and case product is changed from Product X to Product Y,
follow-up E2B is auto scheduled differently depending on the 'Allow Multiple Reports for Marketed/Investigational Drugs' checkbox of the agency at Reporting Destination code list.
If that checkbox is not checked, Follow-up E2B for Product Y is scheduled.
However, if that checkbox is checked, Nullification E2B for Product X and Initial E2B for Product Y are scheduled.
Is this report schedule behavior a bug or expected?
To view full details, sign in with your My Oracle Support account.
Don't have a My Oracle Support account? Click to get started!
In this Document